Randomized Controlled Trials Based on Patient Willingness for Treating Rheumatoid Arthritis with Tibetan Medicine

Not Applicable

• Conditions: rheumatoid arthritis(RA)

• Registration Number: ITMCTR2023000062
• Lead Sponsor: Tibetan Hospital of Xizang Autonomous Region

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 December 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Age range from 18 to 75 years old (including both ends), regardless of gender.

2. Those who meet the diagnostic criteria for rheumatoid arthritis in Western medicine during screening.

3. When screening, it meets the differentiation criteria for Tibetan medicine Changzhong cold syndrome.

4. During screening, it was diagnosed as moderate to low-grade active rheumatoid arthritis (2.6 = baseline DAS28-CRP score = 5.1).

5. Voluntarily sign an informed consent form.

Exclusion Criteria

1. Patients with other rheumatic and immune diseases.

2. Patients with severe cardiovascular and cerebrovascular diseases, kidney disease, and liver disease.

3. Patients with severe infections, tumors, and infectious skin diseases.

4. Patients with late stage deformities, disabilities, or loss of labor in rheumatoid arthritis.

5. Patients with obvious skin lesions and ulcers in the affected area of the joint.

6. Individuals who are allergic to alcohol or experimental drugs.

7. Pregnant or lactating women, or those who are at risk of conception but have not taken effective contraceptive measures during the trial period.

8. Subjects with severe organic lesions, mental disorders, or other reasons who are unable to cooperate with treatment.

9. Those who have used biological agents in the past 3 months.

10. Those who have been participating in other clinical trials for the past month or are currently participating.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of subjects who met ACR20 after 12 weeks of treatment.;